Market Newsdesk

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Applied Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc.

Investors have until February 18, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Applied Therapeutics securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Alexandru v. Applied Therapeutics, Inc., et al., No. 24-cv-09715.

What is the Lawsuit About?

Applied Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases, including Galactosemia.

During the relevant period, the Company stated that its New Drug Applications submitted to regulators for govorestat were “supported by rapid and sustained reduction in galactitol, which resulted in a meaningful benefit on clinical outcomes across pediatric patients, alongside a favorable safety profile.” Applied Therapeutics also assured investors that its tests were “performed properly” and that the Company “felt good about the quality of the data,” stating that it “took really extensive steps” and “actually videotaped” and had “master trainers” review all of the performances of the 10-meter walk-run test—the primary endpoint of the Company’s Phase III INSPIRE study for govorestat.

The Stock Declines as the Truth is Revealed

On November 27, 2024, Applied Therapeutics issued a press release stating that the FDA issued a Complete Response Letter for the NDA for govorestat. The Complete Response Letter stated that the FDA completed its review of the application and determined that it was unable to approve the NDA due to “deficiencies in the clinical application.”

This news caused the price of Applied Therapeutics stock to fall more than 80% over the course of multiple trading days, from a closing price of $10.21 per share on November 26, 2024 to a closing price of $1.75 per share on December 2, 2024.

Then, on December 2, 2024, Applied Therapeutics revealed that it received a warning letter from the FDA relating to its govorestat study discussing “issues related to electronic data capture” and “a dosing error in the dose-escalation phase of the study resulting in slightly lower levels than targeted in a limited number of patients[.]”

This news caused the price of Applied Therapeutics stock to fall more than 26% over the course of multiple trading days, from a closing price of $1.75 per share on December 2, 2024 to a closing price of $1.29 per share on December 5, 2024.

Click here for more information:

https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc

.

What Can You Do?

If you invested in Applied Therapeutics you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) —  Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Symbotic Inc. (NASDAQ: SYM) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Symbotic, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/symbotic-inc.

Investors have until February 3, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Symbotic securities. The case is pending in the U.S. District Court for the District of Massachusetts and is captioned Decker v. Symbotic Inc., et al., No. 24-cv-12976.

What is the Symbotic Class Action Lawsuit About?

Symbotic Inc. develops and operates robotics systems to automate and optimize warehouse and supply chain operations for major retailers and distributors. During the relevant period, the company represented that its financial statements were accurate and that its internal controls over financial reporting were effective.

In contrast with these representations, on November 27, 2024, Symbotic announced a delay in filing its Form 10-K for its fiscal year 2024 due to identified errors in revenue recognition and announced material weaknesses in its internal controls over financial reporting.  Symbotic revealed that it discovered issues related to premature expense recognition and unbillable cost overruns, which affected system revenue recognition in multiple quarters of its fiscal year 2024.  The company estimated a $30–$40 million reduction in system revenue, gross profit, and adjusted EBITDA for its fiscal year 2024 and reduced its revenue outlook for the first quarter of fiscal 2025 to $480–$500 million, from $495–$515 million, and adjusted EBITDA of $12–16 million, from $27–$31 million. 

This news caused the price of the company’s stock to decline over 35% during the course of trading on November 27, 2024.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/symbotic-inc

.

What Can You Do?

If you invested in Symbotic you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/symbotic-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/symbotic-inc

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) —  Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against ASML Holding N.V. (NASDAQ: ASML) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in ASML, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/asml-holding-nv.

Investors have until January 13, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in ASML securities.   The case is pending in the U.S. District Court for the Southern District of New York and is captioned City of Hollywood Firefighters’ Pension Fund v. ASML Holding N.V., et al., No. 24-cv-8664.

What is the Lawsuit About?

ASML is a leading supplier to the semiconductor industry, providing photolithography machines to chipmakers that are used in the semiconductor fabrication process.

The complaint alleges that ASML repeatedly represented to shareholders that new export controls on semiconductor technology announced by the Dutch government would not have a material effect on ASML’s financial outlook, and that ASML was on a path to recovery in its sales.

On October 15, 2024, ASML announced earnings significantly lower than expectations. The Company attributed this to a market that was “taking longer to recover” and admitted that “[i]t now appears the recovery is more gradual than previously expected.” On this news, the price of the Company’s stock fell 16%, from a closing price of $872.27 per share on October 14, 2024, to $730.43 per share on October 15, 2024.

Then, during the accompanying earnings call with investors on October 16, 2024, the Company attributed the poor earnings results to “a reflection of the slow recovery in the traditional [semiconductor] end markets as customers remain cautious in the current environment.” The Company also disclosed that the decline in ASML’s sales to China would also negatively impact the Company’s gross margins. On this news, the price of the Company’s stock fell 6.4%, from a closing price of $730.43 per share on October 15, 2024, to $683.52 per share on October 16, 2024.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/asml-holding-nv

.

What Can You Do?

If you invested in ASML you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/asml-holding-nv

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/asml-holding-nv

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against PACS Group, Inc. (NYSE: PACS) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in PACS, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/pacs-group-inc.

Investors have until January 13, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 11 and 15 of the Securities Act of 1933 and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in PACS securities.   The case is pending in the U.S. District Court for the Southern District of New York and is captioned Manchin v. PACS Group, Inc., et al., No. 24-cv-08636.

What is the PACS Lawsuit About?

The Complaint alleges that PACS is one of the largest operators of skilled nursing facilities in the United States. As alleged, PACS repeatedly represented to shareholders that it possesses a winning “turnaround” strategy to make its nursing facilities profitable. However, in truth, it is alleged that PACS’s turnaround was driven by illicitly accessing Medicare benefits for thousands of patients.

On November 4, 2024, prominent investment research firm Hindenburg Research published a report titled: “PACS Group: How to Become A Billionaire In The Skilled Nursing Industry By Systematically Scamming Taxpayers.” After a 5-month investigation that included interviews with 18 former PACS employees, competitors, and an analysis of more than 900 PACS facility cost reports, Hindenburg alleged that “PACS abused a COVID-era waiver, inappropriately accessing skilled care Medicare benefits for thousands of patients across its national portfolio of facilities.” Hindenburg further estimated that “the scheme drove more than 100% of PACS’ operating and net income from 2020 – 2023, enabling PACS to IPO in early 2024 with the illusion of legitimate growth and profitability.”

On November 6, 2024, PACS then announced that it was postponing its Q3 earnings and that it had “received civil investigative demands from the federal government regarding the Company’s reimbursement and referral practices that may or may not be related to this week’s third-party report.”

The news caused a significant decline in the price of PACS stock. On November 4, 2024, the price of the company’s stock fell 27.8%, from a closing price of $42.94 per share on November 1, 2024, to $31.01 per share on November 4, 2024. On November 6, 2024, the price of the company’s stock fell 38.8%, from a closing price of $29.54 per share on November 5, 2024, to $18.09 per share on November 6, 2024.

Click here if you Suffered Losses:

https://www.bfalaw.com/cases-investigations/pacs-group-inc

.

What Can You Do?

If you invested in PACS you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/pacs-group-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/pacs-group-inc

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) —  Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Marqeta, Inc. (NASDAQ: MQ) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Marqeta, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/marqeta-inc.

Investors have until February 7, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Marqeta securities.   The first-filed case is pending in the U.S. District Court for the Northern District of California and is captioned Wai v. Marqeta, Inc., et al., No. 24-cv-8874.

Why was Marqeta Sued for Securities Fraud?

Marqeta is a financial technology company that provides a card issuing platform, enabling businesses to create and manage customized payment cards. During the relevant period, Marqeta discussed its ability to attract and retain customers while continuing to achieve operational efficiencies given the purported investments it already made into its compliance infrastructure.

In truth, it is alleged that at the time the statements were made, Marqeta experienced longer customer onboarding timelines caused by heightened regulatory scrutiny and insufficient investments into the Company’s compliance apparatus.

The Stock Declines as the Truth is Revealed        

On November 4, 2024, the Company reported its third quarter 2024 financial results and cut its full year 2025 growth outlook, due to “heightened scrutiny of the banking environment and specific customer program changes.” On the earnings call the same day, the Company revealed that “the regulatory scrutiny” had “clearly ratcheted up” in the “first few months of 2024.” Marqeta also admitted that the impact the increased scrutiny had on the Company’s business “became apparent over the last few months.”

This news caused the price of the Company’s stock to fall over 42%, from a closing price of $5.95 per share on November 4, 2024, to $3.42 per share on November 5, 2024.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/marqeta-inc

.

What Can You Do?

If you invested in Marqeta you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/marqeta-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/marqeta-inc

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) —  Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Zeta Global Holdings Corp. (NYSE: ZETA) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Zeta, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/zeta-global-holdings-corp.

Investors have until January 21, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Zeta securities.   The case is pending in the U.S. District Court for the Southern District of New York and is captioned Davoodi v. Zeta Global Holdings Corp., et al., No. 24-cv-08961.

What is the Lawsuit About?

Zeta is a cloud-based technology company that provides a marketing platform to assist marketers in acquiring customers. The complaint alleges that Zeta represented that its marketing platform was powered by the industry’s largest opted-in data set.

On November 13, 2024, prominent investment research firm Culper Research published a report titled: “Zeta Global Holdings Corp (ZETA): Shams, Scams, and Spam.” Based on Culper’s investigation that included proprietary interviews with industry experts and former Zeta employees, the research firm found that Zeta’s data set had been generated from a network of “consent farms” – i.e., sham websites designed to gather consumer data under false pretenses or awards that did not exist. Culper Research further wrote that these consent farms drove almost the entirety of Zeta’s growth over the past 2+ years, representing 56% of its Adjusted EBITDA, and could result in devastating regulatory action.

The news caused a significant decline in the price of Zeta stock. On November 13, 2024, the price of the company’s stock fell 37%, from a closing price of $28.22 per share on November 12, 2024, to $17.76 per share on November 13, 2024.

Click here for more information:

https://www.bfalaw.com/cases-investigations/zeta-global-holdings-corp

.

What Can You Do?

If you invested in Zeta you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/zeta-global-holdings-corp

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/zeta-global-holdings-corp

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ: BIOA) for potential violations of the federal securities laws.

If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

Why is BioAge being Investigated?

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutic products for metabolic diseases, with a primary focus on obesity. The company’s lead product candidate, azelaprag, is an orally available small-molecule agonist of the apelin receptor (APJ), designed to enhance weight loss.

During the relevant period, the company stated that azelaprag was well-tolerated in 265 individuals across eight Phase 1 clinical trials and that following the company’s IPO it was “well-equipped to advance our clinical programs[.]”

The Stock Declines as the Truth is Revealed

On December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns, after liver transaminitis was observed in subjects receiving azelaprag. The company stated that the decision to discontinue the STRIDES Phase 2 study of azelaprag “became clear” due to “the emerging safety profile of the current doses tested[.]”

This news caused the price of the company’s stock to decline over 76%, from a closing price of $20.09 per share on December 6, 2024, to $4.65 per share on December 9, 2024.

Click here for more information:

https://www.bfalaw.com/cases-investigations/bioage-labs-inc

.

What Can You Do?

If you invested in BioAge you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/bioage-labs-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/bioage-labs-inc

Attorney advertising. Past results do not guarantee future outcomes.

BRANFORD, Conn., Dec. 24, 2024 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) reminds holders that its 6.875% unsecured, unsubordinated Notes due December 30, 2024 (“Notes”), ticker symbol “SACC,” will mature on December 30, 2024, as scheduled. The company will redeem the Notes at par plus accrued and unpaid interest up to, but not including, the maturity date.

Sachem expects the last trading day for the Notes will be December 27, 2024.  After the maturity date, no Notes will remain outstanding.

Ticker	CUSIP	Maturity Date	Supplemental and Prospectus Link
SACC	78590A 307	12/30/2024	SEC Filing

Impact on Note Holders

The final payment with respect to the Notes, including principal and accrued interest, will be made on or before December 30, 2024, as described in the prospectus supplement. No action is required by Note holders, and they will be notified directly regarding the details of the redemption process.

About Sachem Capital Corp.

Sachem Capital Corp. is a mortgage REIT that specializes in originating, underwriting, funding, servicing, and managing a portfolio of loans secured by first mortgages on real property. It offers short-term (i.e., three years or less) secured, nonbanking loan to real estate investors to fund their acquisition, renovation, development, rehabilitation, or improvement of properties. The Company’s primary underwriting criteria is a conservative loan to value ratio. The properties securing the loans are generally classified as residential or commercial real estate and, typically, are held for resale or investment. Each loan is secured by a first mortgage lien on real estate and is personally guaranteed by the principal(s) of the borrower. The Company also makes opportunistic real estate purchases apart from its lending activities.

Forward Looking Statements

This press release may contain forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are forward-looking statements. Such forward-looking statements are subject to several risks, uncertainties and assumptions as described in the Annual Report on Form 10-K for 2023 filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 1, 2024 and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the SEC on November 14, 2024. Because of these risks, uncertainties and assumptions, any forward-looking events and circumstances discussed in this press release may not occur. You should not rely upon forward-looking statements as predictions of future events. Neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. The Company disclaims any duty to update any of these forward-looking statements. All forward-looking statements attributable to the Company are expressly qualified in their entirety by these cautionary statements as well as others made in this press release. You should evaluate all forward-looking statements made by the Company in the context of these risks and uncertainties.

Investors:

Email: [email protected]

Singapore, Dec. 24, 2024 (GLOBE NEWSWIRE) — Webuy Global Ltd (Nasdaq: WBUY) (the “Company”) is pleased to announce the remarkable success of its recent Disney cruise campaign, powered by its revolutionary Micky1.0 Travel AI on WhatsApp. By seamlessly integrating advanced AI technology with personalized customer service, Webuy demonstrated its ability to drive significant customer engagement and financial results.

AI-Driven Success

The Disney cruise campaign leveraged Webuy’s digital marketing expertise to direct leads to Micky1.0, the Company’s AI-powered travel assistant. Micky1.0 efficiently answered customer inquiries, provided real-time quotes, and tailored recommendations, before transferring qualified leads to travel consultants for deal closure. This streamlined process highlights the synergy between advanced technology and human expertise.

Outstanding Results

From December 10th to 23rd,2024,  the Disney campaign exclusively drove the following financial achievements:
•    Receivable Booking Value (RBV): SGD 465,527
•    Booking Revenue: SGD 162,202
These figures highlight the significant impact of the Disney project, powered by Webuy’s AI capabilities, on revenue growth.

Driving Value for Customers and Shareholders

“The success of the Disney cruise campaign reflects the strength of our AI-driven approach in enhancing customer experiences and driving sales,” said Vincent Xue Bin, CEO of Webuy Global Ltd. “We’re excited about the future as we scale Micky1.0 and similar innovations to unlock greater value for our customers and shareholders.”

Expanding Opportunities in Travel

As Webuy continues to grow its travel services, the Company remains committed to integrating cutting-edge AI technologies like Micky1.0 with its core offerings, paving the way for future success in the Southeast Asian market and beyond.

About Webuy Global Ltd

Webuy Global Ltd (Nasdaq: WBUY) is a forward-thinking, technology-driven company aimed at becoming the leading e-commerce and travel platform in Southeast Asia. Leveraging advanced AI technologies, the Company enhances its ‘group buy’ model by providing personalized recommendations, predictive demand analytics, and seamless community interactions. In addition, Webuy integrates AI-powered travel solutions, such as its proprietary AI Travel Consultant, to deliver personalized itineraries, group travel planning, and real-time support. These innovations streamline the traditional supply chain, foster a community-driven shopping experience, and simplify travel planning for its users. Webuy is committed to improving the lives of millions of families in Southeast Asia with high-quality, affordable products, services, and travel experiences. For more information, visit https://www.webuysg.com/Investor/

WeBuy Global Ltd.
Email: [email protected]

Proceeds expected to extend cash runway to fund operations into at least the next 24 months 

SHOHAM, Israel, Dec. 24, 2024 (GLOBE NEWSWIRE) —

Mobilicom
Limited
(Nasdaq: MOB), a provider of cybersecurity and robust solutions for drones and robotics, today announced that holders of warrants to purchase 761,290 ADRs issued in the Company’s registered direct offering in January 2024, have exercised their warrants for aggregate gross proceeds of approximately $1.2 million.

“Over the past month, we’ve seen our company’s valuation increase over 150%, and this has created economics that encouraged some of our institutional investors to exercise warrants. With this latest cash injection, our balance sheet is further fortified, which we expect to give us a cash runway of at least 24 months, which may be further extended as adoption of our drone technologies are increasingly gaining traction in a high-growth market. Our most recently reported financial results for the first half of 2024 demonstrate that our revenues more than tripled, gross margins increased, net loss narrowed and net cash used in operating activities halved compared to the same period in 2023,” stated Mobilicom CEO and Founder Oren Elkayam. “We believe the favorable market dynamics at this time for military and civilian drone and robotics indicate Mobilicom will have a strong 2025.” 

About Mobilicom

Mobilicom is a leading provider of cybersecure robust solutions for the rapidly growing defense and commercial drones and robotics market.  Mobilicom’s large portfolio of field-proven technologies includes cybersecurity, software, hardware, and professional services that power, connect, guide, and secure drones and robotics. Through deployments across the globe with over 50 customers, including the world’s largest drone manufacturers, Mobilicom’s end-to-end solutions are used in mission-critical functions.

For investors, please use https://ir.mobilicom.com/ 
For company, please use www.mobilicom.com

Forward Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. For example, the Company is using forward-looking statements when it discusses its how with this latest cash injection, its balance sheet is further fortified, which it expects to give it a cash runway of at least 24 months, which may be further extended as adoption of its drone technologies are increasingly gaining traction in a high-growth market and its belief that the favorable market dynamics at this time for military and civilian drone and robotics indicate Mobilicom will have a strong 2025. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Mobilicom Limited’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Mobilicom Limited undertakes no duty to update such information except as required under applicable law.

For more information on Mobilicom, please contact:

Liad Gelfer

Mobilicom Ltd
[email protected]